

Supplemental Figure S1: GRADE level of certainty for fluvoxamine compared to placebo for COVID-19

Question: Fluvoxamine compared to Placebo for COVID-19

Setting: Outpatients

No of studies	Study design	Certainty assessment					No of patients		Effect		Certainty	Importance
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fluvoxamine	Placebo	Relative (95% CI)	Absolute (95% CI)		
Primary Outcome												
3	randomised trials	not serious ^a	Serious ^b	not serious ^c	not serious ^d	none	94/1093 (8.6%)	143/1103 (13.0%)	RR 0.69 (0.54 to 0.88)	40 fewer per 1,000 (from 60 fewer to 16 fewer)	⊕⊕⊕○ Moderate	IMPORTANT
Hospitalization												
3	randomised trials	not serious ^a	not serious ^d	not serious ^g	not serious ^h	none	84/1093 (7.7%)	111/1103 (10.1%)	RR 0.79 (0.60 to 1.03)	21 fewer per 1,000 (from 40 fewer to 3 more)	⊕⊕⊕⊕ High	IMPORTANT

CI: confidence interval; RR: risk ratio

Explanations

- a. No issues were detected as studies have a low risk of bias
- b. Outcomes are not directly comparable as a combination of clinical deterioration and hospitalization is used
- c. No issues were detected with indirectness
- d. No issues were detected with imprecision
- e. No issues were detected as studies have a low risk of bias
- f. No issues were detected as outcomes are directly comparable
- g. No issues were detected with indirectness
- h. No issues were detected with imprecision